While antibody-drug conjugates have widespread treatment potential, the successful and safe manufacturing of these highly potent drugs requires a highly skilled team of experts and well-controlled manufacturing facilities. ADCs consist of three parts: an antibody specific to the target associated antigen, a payload designed to kill target cancer cells, and a chemical linker to attach the payload to the antibody.
We have leading capabilities and expertise in development across the ADC manufacturing parts: antibodies, payloads, linker and bioconjugation and sterile fill and finish. This integrated capability for the development and manufacture of ADC products can accelerate program timelines and reduce program complexity, resource requirements and risk.
- Antibodies
- Payloads
- Bioconjugation
- Sterile fill and finish
We operate GMP production suites for gram-scale ADC payload production and multi-kilogram-scale production capacity at our site in Visp, Switzerland. End-to-end service programs can be readily arranged to meet your program needs. You can utilize our unique infrastructure for ADC payloads and overall ADC capabilities to avoid extra investment in expertise, assets and infrastructure required to work with these very highly potent applications.
- cGMP lab suites
- Advanced synthesis
- OEL levels of 100ng- 1ng
- Gram-scale and multi-kilogram scale
An integrated ADC CDMO can provide development and manufacturing services across the entire ADC value chain, including antibodies, payloads, linkers, bioconjugation, and sterile fill-finish. Working with a single partner helps simplify technology transfer, reduce supply chain complexity, and accelerate timelines from clinical development to commercial supply.
When selecting an ADC manufacturing partner, look for expertise in highly potent compounds, scalable GMP manufacturing, integrated ADC capabilities, regulatory support, and experience supporting both clinical and commercial programs. A partner with expertise across payloads, linkers, bioconjugation, and drug product manufacturing can help reduce development risk and streamline commercialization.
Yes, some ADC CDMOs offer end-to-end services that support payload development, linker manufacturing, antibody production, bioconjugation, sterile fill-finish, and commercial manufacturing. This integrated approach can reduce coordination between multiple vendors and help accelerate project timelines.
ADC payload manufacturing requires specialized containment systems, highly potent API (HPAPI) expertise, advanced synthesis capabilities, and GMP facilities designed to safely handle compounds with very low occupational exposure limits. These capabilities are essential for maintaining product quality and operator safety throughout development and commercialization.
Integrated ADC manufacturing reduces handoffs between suppliers by bringing payload, linker, antibody, bioconjugation, and drug product capabilities together under one quality system. This can improve project coordination, reduce supply chain risks, and help move ADC candidates more efficiently from development to commercial supply.
ADC manufacturing partners may offer production ranging from gram-scale quantities for early clinical development through multi-kilogram-scale commercial manufacturing. Access to scalable GMP capacity can help ensure a smooth transition as program requirements grow.
Each ADC component influences the safety, efficacy, and manufacturability of the final product. A manufacturing partner with expertise in payload chemistry, linker technologies, and bioconjugation can help optimize development strategies, improve process robustness, and support successful clinical and commercial outcomes.